|The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Results of a single-arm, open-label, phase 2 study showed pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide was well tolerated in women with heavily pretreated recurrent ovarian cancer. Furthermore, response rates for this combination were higher compared with historical controls of similar populations treated with single-agent pembrolizumab or bevacizumab/cyclophosphamide chemotherapy. These findings were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.
Researchers enrolled 40 patients with recurrent epithelial ovarian cancer for the study. Although the majority of patients had platinum-resistant disease, 25% had disease that was classified as platinum-sensitive. The treatment regimen consisted of intravenous (IV) administration of 200 mg pembrolizumab in combination with bevacizumab 15 mg/kg IV every 3 weeks and daily administration of 50 mg of oral cyclophosphamide until disease progression or unacceptable toxicity. The primary objectives of the study included assessments of safety, overall response rate (ORR), and progression-free survival (PFS).
At the time of the interim analysis, with a median follow-up of 14.7 months, the ORR was 37.5% and the 6 month PFS rate was 70%, with 18% of patients having undergone more than 12 months of treatment. Of note, 6 month PFS rates were significantly higher in patients with platinum-sensitive disease compared with patients with non-platinum sensitive disease (100% vs 59%; P =.024).
Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.
- Zsiros E, Frederick PJ, Akers SN, et al. A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, Fallopian tube or primary peritoneal cancer. Presented at: 2019 Annual Meeting of the Society of Gynecologic Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract LBA4.